Literature DB >> 10582589

The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer's amyloid precursor protein.

S S Petanceska1, S Gandy.   

Abstract

One of the hallmarks of Alzheimer's disease is the accumulation of senile plaques in brain, extracellular lesions comprised mostly of aggregates of the amyloid beta-peptide (Abeta). Abeta is proteolytically derived from the Alzheimer's amyloid precursor protein (APP). The generation of Abeta and nonamyloidogenic derivatives of APP involves utilization of alternative processing pathways and multiple subcellular compartments. To improve our understanding of the regulation of APP processing, we investigated the effects of wortmannin, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, on APP processing. PI3-kinases form a multifaceted family of enzymes that represent converging points for multiple signal transduction pathways and also act as key regulators of vesicular trafficking. In N2a neuroblastoma cells expressing either wild-type APP or the "Swedish" familial Alzheimer's disease-associated mutant variant of APP, wortmannin treatment resulted in decreased release of both Abeta and soluble APPalpha. In parallel, full-length APP and both processed derivatives accumulated inside the cells. These effects were not present at nanomolar concentrations of wortmannin, but only at micromolar concentrations, implying the possible involvement of a recently described trans-Golgi network (TGN)-associated PI3-kinase that is resistant to nanomolar concentrations of the inhibitor, but sensitive to micromolar concentrations. All effects were reversible when the drug was removed from the cell culture medium. Given the suspected site of action of this novel PI3-kinase activity at the TGN, it is tempting to speculate that the unexpected increase in the levels of both intracellular soluble APPalpha and intracellular Abeta might be due to wortmannin-induced covesiculation of APP together with its respective secretase enzymes within the TGN, leading to the execution of alpha-, beta-, and gamma-secretase reactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582589     DOI: 10.1046/j.1471-4159.1999.0732316.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Effects of staurosporine, U-73122, wortmannin, 4-hydroxynonenal and sodium azide upon the release of secreted beta-amyloid precursor protein from human platelets in response to thrombin stimulation.

Authors:  H L Hedin; L Nilsson; C J Fowler
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

Review 2.  Obesity, leptin, and Alzheimer's disease.

Authors:  Edward B Lee
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

3.  The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3β pathway mediates bilobalide-induced reduction in amyloid β-peptide.

Authors:  Chun Shi; Dong-dan Zheng; Feng-ming Wu; Jun Liu; Jie Xu
Journal:  Neurochem Res       Date:  2011-09-28       Impact factor: 3.996

4.  Ellagic acid prevents dementia through modulation of PI3-kinase-endothelial nitric oxide synthase signalling in streptozotocin-treated rats.

Authors:  Manish Kumar; Nitin Bansal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-15       Impact factor: 3.000

Review 5.  Linking lipids to Alzheimer's disease: cholesterol and beyond.

Authors:  Gilbert Di Paolo; Tae-Wan Kim
Journal:  Nat Rev Neurosci       Date:  2011-03-30       Impact factor: 34.870

Review 6.  Alois Alzheimer revisited: differences in origin of the disease carrying his name.

Authors:  K Maurer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

7.  EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP.

Authors:  Jamie Winderbaum Fernandez; Kavon Rezai-Zadeh; Demian Obregon; Jun Tan
Journal:  FEBS Lett       Date:  2010-09-17       Impact factor: 4.124

8.  Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase.

Authors:  Diana W Shineman; Aleksandra S Dain; Minkyu L Kim; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

9.  A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.

Authors:  Tapan K Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon
Journal:  Neurobiol Dis       Date:  2009-02-20       Impact factor: 5.996

10.  Diabetes and Alzheimer's disease - is there a connection?

Authors:  Anders A F Sima; Zhen-Guo Li
Journal:  Rev Diabet Stud       Date:  2007-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.